Pharmaceutical major Roche saw its pharmaceutical division sales total CHF28.4bn, an increase of 5% excluding influenza antiviral Tamiflu.

Its diagnostics division also witnessed sales growth of 8%, ahead of the global diagnostics market, to CHF7.7bn

Despite reduced Tamiflu sales and what Roche has labelled as a more challenging market environment, the company confirmed its full-year outlook for 2010 expected sales growth in the mid-single-digit range for the group.

In September, Roche was named Supersector Leader in Healthcare in the Dow Jones Sustainability Indexes for the second year running.